Aging and the hemopoietic system

Critical Reviews in Oncology/Hematology

Volumn 48, Issue SUPPL., 2003, Pages

  Pinto, Antonio ^a   De Filippi, Rosaria ^b   Frigeri, Ferdinando ^a   Corazzelli, Gaetano ^a   Normanno, Nicola ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aging; Chemotherapy; Dendritic cell; Hemopoiesis; Stem cell

Indexed keywords

CYCLOPHOSPHAMIDE; DAUNORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE SULFATE;

AGING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DENDRITIC CELL; FEVER; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNOCHEMISTRY; IMMUNOTHERAPY; NEUTROPENIA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEM CELL; TREATMENT OUTCOME;

EID: 0141918769     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.06.006     Document Type: Conference Paper

References (59)

1. Repetto L., Balducci L. A case for geriatric oncology. Lancet Oncol. 3:2002;289-297.
2. Balducci L., Hardy C.L., Lyman G.H. Hematopoietic growth factors in the older cancer patient. Curr. Opin. Hematol. 8:2001;170-187.
3. Yancik R., Ries L.A.G. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol. Oncol. Clin. N. Am. 14:2000;17-23.
4. Coiffier B. Non-Hodgkin lymphoma in the elderly. Therapeutic strategies and results in clinical trials. Ann. Oncol. 9(Suppl 3):1998;19-26.
5. Zagonel V., Monfardini S., Tirelli U., Carbone A., Pinto A. Management of hematologic malignancies in the elderly: 15-year experience at the Aviano Cancer Center, Italy. Crit. Rev. Oncol. Hematol. 39:2001;289-305.
6. Pinto A., Zagonel V., Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit. Rev. Oncol. Hematol. 39:2001;275-287.
7. Kouroukis C.T., Browman G.P., Esmail R., Meyer R.M. Chemotherapy for older patients with newly diagnosed, advanced stage, aggressive histology non-Hodgkin lymphoma: a systematic review. Ann. Intern. Med. 136:2002;144-152.
8. Balducci L., Lyman G.H. Patients aged ≥70 are at high risk for neutropenic infection and should receive hemopoietic growth factors when treated with moderately toxic chemotherapy. J. Clin. Oncol. 18:2000;3558-3585.
9. Gaynor E., Dahlberg S., Fisher R. Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: an analysis of SWOG-8516 (INT 0067). Proc. Am. Soc. Clin. Oncol. 13:1994;370. (1250).
10. Gilleece M.H., Dexter T.M. The biological ageing of bone marrow. Rev. Clin. Gerontol. 3:1993;317-325.
11. Inelmen E.M., D'Alessio M., Gatto M.R.et al. Descriptive analysis of the prevalence of anemia in a randomly selected sample of elderly people living at home: some results of an Italian multicentric study. Aging (Milano). 6:1994;81-89.
12. Rothstein G. Hematopoiesis in the aged: a model of hematopoietic dysregulation? Blood. 82:1993;2601-2604.
13. Fernandez-Ferrero S., Ramos F. Dyshaemopoietic bon marrow features in healthy subjects are related to age. Leuk. Res. 25:2001;187-189.
14. Vaziri H., Dragowska W., Allsopp R.C., Thomas T.E., Harley C.B., Lansdorp P.M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl. Acad. Sci. U.S.A. 91:1994;9857-9860.
15. Van Zant G. Stem cells and genetics in the study of development. Results Probl. Cell Differ. 29:2000;203-235.
16. Robertson J.D., Gale R.E., Wynn R.F.et al. Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br. J. Haematol. 109:2000;272-279.
17. Zeichner S.L., Palumbo P., Feng Y.et al. Rapid telomere shortening in children. Blood. 93:1999;2824-2830.
18. Monteiro J., Batiwalla F., Ostere H., Gregersen P.K. Shortened telomeres in clonally expanded CD28-CD8+T cell imply a replicative history that is distinct from their CD28+CD8+ counterparts. J. Immunol. 156:1996;3587-3590.
19. Albright J.W., Makinodan T. Decline in the growth potential of spleen-colonizing bone marrow stem cells of long-lived aging mice. J. exp. Med. 144:1976;1204-1213.
20. Zaucha J.M., Yu C., Mathioudakis G.et al. Hematopoietic responses to stress conditions in young dogs compared with elderly dogs. Blood. 98:2001;322-327.
21. Busque L., Mio R., Mattioli J.et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood. 88:1996;59-65.
22. Gale R.E., Fielding A.K., Harrison C.N., Linch D.C. Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Br. J. Haematol. 98:1997;512-519.
23. Champion K.M., Gilbert J.G., Asimakopoulos F.A., Hinshelwood S., Green A.R. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br. J. Haematol. 97:1997;920-926.
24. Abkowitz J.L., Taboada M., Shelton G.H., Catlin S.N., Guttorp P., Kiklevich J.V. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3862-3866.
25. Christensen K., Kristiansen M., Hagen-Larsen H.et al. X-linked genetic factors regulate hematopoietic stem-cell kinetics in females. Blood. 95:2000;2449-2451.
26. Geiger H., True J.M., de Haan G., Van Zant G. Age- and stage-specific regulation patterns in the hematopoietic stem cell hierarchy. Blood. 98:2001;2966-2972.
27. Lipschytz D.A. Age-related decline in hemopoietic reserve capacity. Semin. Oncol. 22(Suppl 1):1995;3-6.
28. Bagnara G.P., Bonsi L., Strippoli P.et al. Hemopoiesis in healthy old people and centenarian well maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodelling of cytokine network. J. Gerontol. A Biol. Sci. Med. Sci. 55:2000;B61-B70.
29. Egusa Y., Fujiwara Y., Syahruddin E., Isobe T., Yamakido M. Effect of age on human peripheral blood stem cells. Oncol. Rep. 5:1998;397-400.
30. Chatta G.S., Price T.H., Allen R.C., Dale D.C. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood. 84:1994;2923-2929.
31. Marley S.B., Lewis J.L., Davidson R.J.et al. Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children. Br. J. Haematol. 106:1999;162-166.
32. Resnitzky P., Segal M., Barak Y., Dassa C. Granulopoiesis in aged people: inverse correlation between bone marrow cellularity and myeloid progenitor cell numbers. Gerontology. 33:1987;109-114.
33. Sudo K., Ema H., Morita Y., Nakauchi H. Age-associated characteristics of murine hematopoietic stem cells. J. Exp. Med. 192:2000;1273-1280.
34. Balducci L., Hardy C.L., Lyman G.H. Hemopoietic reserve in the older cancer patients: clinical and economic considerations. Cancer Control. 7:2000;539-547.
35. Carmel R. Anemia and aging: an overview of clinical. Blood Rev. 15:2001;9-18.
36. Jiang D.Z., Fei R.-G., Pendergrass W.R., Wolf N.S. An age-related reduction in the replicative capacity of two murine hematopoietic stroma cell types. Exp. Hematol. 20:1992;1216-1222.
37. Gazit D., Zilberman Y., Turgeman G., Zhou S., Kahn A. Recombinant TGF-beta1 stimulates bone marrow osteoprogenitor cell activity and bone matrix synthesis in osteopenic, old male mice. J. Cell Biochem. 73:1999;379-389.
38. Banchereau J., Briere F., Caux C.et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:2000;767-811.
39. Utemura K., Castle S.C., Makinodan T. The frail elderly: role of dendritic cells in the susceptibility of infection. Mech. Ageing. Dev. 123:2002;955-962.
40. Grewe M. Chronological ageing and photoageing of dendritic cells. Clin. Exp. Dermatol. 26:2001;608-612.
41. Lung T.L., Saurwein-Teissl M., Parson W. Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells. Vaccine. 18:2000;1606-1612.
42. Pietschmann P., Hahn P., Kudlacek S.et al. Surface markers and transendothelial migration of dendritic cells from elderly subjects. Exp. Gerontol. 35:2000;213-224.
43. Bhushan M., Cumberbath M., Dearman R.J.et al. Tumor necrosis factor-alpha-induced migration of human Langerhans cells: the influence of ageing. Br. J. Dermatol. 146:2002;32-40.
44. Schmucker D.L., Thoreux K., Owen R.L. Aging impairs intestinal immunity. Mech. Ageing Dev. 122:2001;1397-1411.
45. Extermann M., Overcash J., Lyman G.H.et al. Comorbidity and functional status are independent in old cancer patients. J. Clin. Oncol. 16:1998;1582-1587.
46. Looney R.J., Falsey A.R., Walsh E.et al. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis. 185:2002;682-685.
47. Bourguin-Plonquet A., Rouard H., Roudot-Thoraval F.et al. Severe decrease in peripheral blood dendritic cells in hair cell leukemia. Br. J. Haematol. 116:2002;595-597.
48. Extermann M. Acute leukemia in the elderly. Clin. Geriatr. Med. 13:1997;227-244.
49. O'Reilly S.E., Connors J.M., Macpherson N.et al. Malignant lymphomas in the elderly. Clin. Geriatr. Med. 13:1997;251-264.
50. Thigpen JT. Ovarian cancer in the older patient. In: Balducci L, Lyman GH, Ershler WB, editors. Comprehensive geriatric oncology. Amsterdam, The Netherlands: Harwood Academy Publishers; 1998. p. 721-32.
51. Kwak L.W., Halpern J., Olshen R.A., Hornig S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol. 8:1990;963-977.
52. Lepage E., Gisselbrecht C., Haioun C.et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann. Oncol. 4:1993;651-656.
53. Lyman G.H., Kuderer N.M., Balducci L. Cost-benefit analysis of granulocyte colony stimulating factors in the management of elderly cancer patients. Curr. Opin. Hematol. 9:2002;207-214.
54. Sonneveld P., de Ridder M., van der Lelie H.et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J. Clin. Oncol. 13:1995;2530-2539.
55. Tirelli U., Errante D., van Glabbeke M.et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer - Lymphoma Cooperative Study Group. J. Clin. Oncol. 16:1998;27-34.
56. Zinzani P.L., Storti S., Zaccaria A.et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 94:1999;33-38.
57. Fisher R.I., Gaynor E.R., Dahlberg S.et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1993;1002-1006.
58. Pfreundschuh M, Trümper L, Kloess M, et al. Two-weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Ann Oncol 2002;13(Suppl 2):27 (081).
59. Pfreundschuh M, Trümper L, Kloess M, et al. CHOEP (CHOP + Etoposide) is the new standard regimen for young patients with low-risk (low LDH) aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13(Suppl 2):74 (244).